FDA Panel Rejects Lipocine's Testosterone Pill Post author:Sam Post published:January 10, 2018 Post category:BioPharma The FDA voted six in favor and thirteen against the benefit/risk profile of TLANDO. Source: BioSpace You Might Also Like Takeda CEO Actively Hunts for Deals, Looks to Shed Non-Core Businesses November 16, 2017 Abiomed Will Pay $3.1 Million to Settle Kickback Allegations March 8, 2018 Inventiva Announces First-Half 2017 Financial And Corporate Update July 5, 2017
